These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26916894)

  • 1. Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.
    Vivenza D; Monteverde M; Lattanzio L; Tonissi F; Astesana V; Denaro N; Comino A; Russi E; Lo Nigro C; Merlano M
    Int J Biol Markers; 2016 May; 31(2):e183-92. PubMed ID: 26916894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
    Vivenza D; Gasco M; Monteverde M; Lattanzio L; Syed N; Colantonio I; Denaro N; Natoli G; Comino A; Russi E; Merlano M; Crook T; Lo Nigro C
    Oral Oncol; 2012 Jul; 48(7):602-7. PubMed ID: 22356895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma.
    Nakashima M; Kondo S; Shimizu Y; Wakisaka N; Murono S; Furukawa M; Yoshizaki T
    Acta Otolaryngol; 2008 Jul; 128(7):808-13. PubMed ID: 18568525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
    Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
    Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
    Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 and TP53 Polymorphisms as Predictive Markers for Head and Neck Cancer in Northeast Indian Population: Effect of Gene-Gene and Gene-Environment Interactions.
    Bhowmik A; Das S; Bhattacharjee A; Choudhury B; Naiding M; Deka S; Ghosh SK; Choudhury Y
    Asian Pac J Cancer Prev; 2015; 16(14):5767-72. PubMed ID: 26320449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.
    Shinohara A; Sakano S; Hinoda Y; Nishijima J; Kawai Y; Misumi T; Nagao K; Hara T; Matsuyama H
    Cancer Sci; 2009 Dec; 100(12):2376-82. PubMed ID: 19764997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women.
    Zając A; Smolarz B; Stachowiak G; Wilczyński JR
    Med Oncol; 2014 Nov; 31(11):286. PubMed ID: 25316267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
    Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
    Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fuzzy clustering demonstrates that codon 72 SNP rs1042522 of TP53 gene associated with HNSCC but not with prognoses.
    Pinheiro UB; Fraga CA; Mendes DC; Farias LC; Cardoso CM; Silveira CM; D'Angelo MF; Jones KM; Santos SH; de Paula AM; Guimarães AL
    Tumour Biol; 2015 Dec; 36(12):9259-65. PubMed ID: 26099726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.
    Dong J; Ren B; Hu Z; Chen J; Hu L; Dai J; Jin G; Xu L; Shen H
    Mol Carcinog; 2011 Jun; 50(6):433-8. PubMed ID: 21268124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
    Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
    Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.